بحث بسيط
السجلات المعروضة 1 -- 10 من 30
Protection against the omicron variant from previous SARS-CoV-2 infection
(
Massachusetts Medical Society
, 2022 , Other)
Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...
Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: Mathematical modelling analyses
(
BMJ Publishing Group
, 2021 , Article)
Background Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient ...
Detection of antinuclear antibodies targeting intracellular signal transduction, metabolism, apoptotic processes and cell death in critical COVID-19 patients
(
Qatar University Press
, 2021 , Poster)
Background: The heterogeneity of COVID-19 lies within its diverse symptoms and severity, ranging from mild to lethal. Acute respiratory distress syndrome (ARDS) has been shown to be the leading cause of mortality in COVID-19 ...
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
(
Elsevier
, 2021 , Article)
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons ...
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
(
Elsevier
, 2021 , Article)
The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens ...
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
(2021 , Article)
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...
Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
(
MDPI
, 2022 , Report)
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was ...
Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
(
Frontiers Media
, 2022 , Article)
In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy ...
Effect of multiple freeze–thaw cycles on the detection of anti-SARS- CoV- 2 IgG antibodies
(
Microbiology Society
, 2021 , Article)
Several studies have investigated the effect of repeated freeze-thaw (F/T) cycles on RNA detection for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, no data are available regarding the effect of ...
Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France
(
Elsevier
, 2021 , Article)
In light of the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there remain unanswered questions regarding the humoral immune response and ...